NovaQuest Capital Management is raising a new investment fund. And it is kicking off with at least $75 million, the Raleigh-based firm disclosed Monday.

The group of financial investors who spun out NovaQuest in 2010 from Quintiles to focus on life science investments, closed on a fund worth $459 million in 2013.

The new fund was disclosed in a securities filing.

NovaQuest Pharma Opportunities Fund IV has already drawn one investor of $75 million.

The company has not responded to a request for comment.

Last year, NovaQuest teamed with Longitude Capital to acquire California Cyrobank, which provides reproductive tissue donor services and storage.

NovaQuest has publicly disclosed three investments since 2013:

  • Up to $85 million for drug development at Shionogi
  • Up to $40 million in Pharmaxis
  • Up to $150 million in Hospira

In 2014, NovaQuest also made an “exit” when Precision Dermatology was acquired by Canada-based Valeant in a deal worth $475 million.

NovaQuest’s website also reports 16 other investments.

Quintiles formed NovaQuest as an investment group in 2006.

The last fund-raise closed in October 2013.

“We are extremely pleased to have a mix of high-quality, limited partners who have entrusted their capital to us, and who are supportive of our unusual, alternative offering that seeks to earn returns primarily from the important products of mid- and large-size biopharmaceutical companies,” said Ron Wooten, Managing Partner and Chief Investment Officer of NovaQuest, at the time.

“The global biopharmaceutical industry faces many challenges as it seeks to bring new and beneficial medicines and therapies to patients. We believe these challenges and the demand to improve healthcare globally should provide many opportunities for NovaQuest to make investments that both help patients and give our limited partners the chance to earn attractive returns on their investments.”